Patent Assignment
Reel/Frame 059437/0654
Security Interest
Recorded: 2022-03-18
Pages: 8
Assignor
REVANCE THERAPEUTICS, INC.
Executed: 2022-03-18
Assignee
ATHYRIUM BUFFALO LP
C/O ATHYRIUM CAPITAL MANAGEMENT, LP, 505 FIFTH AVENUE, FLOOR 18, NEW YORK, NEW YORK, 10017
Covered Properties
(55)
Topical Ocular Preparation of Botulinum Toxin for Use in Ocular Surface Disease
Use of Botulinum Toxin for the Treatment of Cerebrovascular Disease, Renovascular and Retinovascular Circulatory Beds
Use of Botulinum Toxin for the Treatment of Cerebrovascular Disease, Renovascular and Retinovascular Circulatory Beds
Injectable Botulinum Toxin Formulations
Injectable Botulinum Toxin Formulations
Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins
Compositions and methods for topical application and transdermal delivery of botulinum toxins
Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins
Compositions and Methods for Topical Diagnostic and Therapeutic Transport
Compositions and Methods for Topical Diagnostic and Therapeutic Transport
Antimicrobial Peptide, Compositions, and Methods of Use
Albumin-Free Botulinum Toxin Formulations
Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins
Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins
Methods for Treating Pain by Topical Application and Transdermal Delivery of Botulinum Toxin
Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins
Compositions and Methods for Treating Acne
Compositions and Methods for Safe Treatment of Rhinitis
Selection of Patients with Increased Responsiveness to Botulinum Toxin
Treatment of sinusitis related chronic facial pain and headache with botulinum toxin injections
Composition for Therapeutic and Cosmetic Botulinum Toxin
Pharmaceutical Botulinum Toxin Compositions
High-Potency Botulinum Toxin Formulations
Composition for therapeutic and cosmetic botulinum toxin
Pharmaceutical Botulinum Toxin Compositions
High-Potency Botulinum Toxin Formulations
Extended Length Botulinum Toxin Formulation for Human or Mammalian Use
Extended Length Botulinum Toxin Formulation for Human or Mammalian Use
Treatment of Chronic Chalazion and Hordeolum with Botulinum Toxin
Treatment of Chronic Chalazion and Hordeolum with Botulinum Toxin
Methods of Using Botulinum Toxin for the Treatment of Hypervolemic Lip Deformity (Lip Ectropion)
Compositions, Methods and Devices for Preparing Less Painful Botulinum Toxin Formulations
Methods and Systems for Purifying Non-Complexed Botulinum Neurotoxin
Methods and Systems for Purifying Non-Complexed Botulinum Neurotoxin
Methods and Kits for Topical Application, Removal, and Inactivation of Therapeutic or Cosmetic Toxin Compositions
Application:
13/978,673 →
Publication:
US US20140154237A1
Methods and Kits for Topical Application, Removal, and Inactivation of Therapeutic or Cosmetic Toxin Compositions
Application:
17/114,486 →
Publication:
US US20210189326A1
Topical Ocular Preparation of Botulinum Toxin for Use in Ocular Surface Disease
Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
Application:
17/135,938 →
Publication:
US US20210252116A1
Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
Application:
17/183,934 →
Publication:
US US20210283228A1
Arginine Heteromers for Topical Administration
Arginine Heteromers for Topical Administration
Injectable Botulinum Toxin Formulations and Methods of Use Thereof Having High Response Rate and Long Effect Duration
Application:
16/770,033 →
Publication:
US US20200384090A1
Transmucosal Botulinum Toxin Compositions, Kits, and Methods for Treating Bladder Disorders
Albumin-Free Botulinum Toxin Formulations
Albumin-Free Botulinum Toxin Formulations
Albumin-Free Botulinum Toxin Formulations
Compositions and Methods for Topical Diagnostic and Therapeutic Transport
Methods and Compositions for Treating Skin Conditions Associated With Vascular Hyper-reactivity
Application:
16/984,036 →
Publication:
US US20220347275A1
Injectable Botulinum Toxin Formulations And Methods Of Use Thereof Having Long Duration Of Therapeutic Or Cosmetic Effect
Application:
17/472,525 →
Publication:
US US20220062400A1
Methods of Treatment for Cervical Dystonia
Methods of Treating Upper Limb Spasticity With Botulinum Toxin
Application:
63/151,795 →
Injectable Botulinum Toxin Methods for Treating Headaches
PCT:
PCT/US2021/023046 ↗
Methods for Treating Cervical Dystonia
PCT:
PCT/US2021/054818 ↗
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jul 6, 2005
From: DAKE, MICHAEL D.; WAUGH, JACOB M.
To: ESSENTIA BIOSYTEMS, INC.
Reel/Frame 016755/0031 →
Assignment of Assignor's Interest
Dec 13, 2006
From: DAKE, MICHAEL D.; WAUGH, JACOB M.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 018628/0598 →
Assignment of Assignor's Interest
Dec 13, 2006
From: DAKE, MICHAEL D.; WAUGH, JACOB M.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 018628/0455 →
Assignment of Assignor's Interest
Dec 13, 2006
From: DAKE, MICHAEL D.; WAUGH, JACOB M.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 018628/0419 →
Assignment of Assignor's Interest
Dec 13, 2006
From: DAKE, MICHAEL D.; WAUGH, JACOB M.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 018628/0284 →
Assignment of Assignor's Interest
Oct 6, 2008
From: DAKE, MICHAEL D.; WAUGH, JACOB M.
To: REVANCE THERAPEUTICS, INC
Reel/Frame 021639/0144 →
Assignment of Assignor's Interest
Oct 7, 2008
From: WAUGH, JACOB M.; LEE, JAE HOON
To: REVANCE THERAPEUTICS, INC
Reel/Frame 021662/0606 →
Change of Name
Mar 20, 2009
From: ESSENTIA BIOSYSTEMS, INC.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 022431/0053 →
Security Agreement
May 29, 2009
From: REVANCE THERAPEUTICS, INC.
To: LEADER VENTURES, LLC
Reel/Frame 022756/0549 →
Assignment of Assignor's Interest
Feb 3, 2010
From: STONE, HONGRAN FAN; WAUGH, JACOB M.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 023889/0346 →
Security Agreement
May 24, 2010
From: REVANCE THERAPEUTICS, INC.
To: LEADER VENTURES, LLC
Reel/Frame 024432/0321 →
Assignment of Assignor's Interest
Jul 19, 2011
From: RUEGG, CURTIS L.; STONE, HONGRAN FAN; WAUGH, JACOB M.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 026612/0278 →
Security Agreement
Sep 22, 2011
From: REVANCE THERAPEUTICS, INC.
To: HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
Reel/Frame 026953/0726 →
Release of Security Interest Recorded at Reel/Frame 24432/321, 24432/284, 24432/317, 22432/187, and 22756/549
Oct 4, 2011
From: LEADER VENTURES, LLC
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 027015/0658 →
Assignment of Assignor's Interest
Mar 24, 2016
From: BORODIC, GARY E, DR; ACQUADRO, MARTIN A, DR
To: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
Reel/Frame 038249/0697 →
Assignment of Assignor's Interest
Mar 24, 2016
From: BORODIC, GARY E, DR
To: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
Reel/Frame 038249/0590 →
Assignment of Assignor's Interest
Jun 3, 2016
From: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 038870/0160 →
Assignment of Assignor's Interest
Apr 25, 2019
From: DRAKE, MICHAEL D.; WAUGH, JACOB M.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 048989/0460 →
Release of Security Interest
Sep 27, 2019
From: HERCULES CAPITAL, INC. (F/K/A HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 050565/0300 →
Assignment of Assignor's Interest
Mar 17, 2022
From: DAKE, MICHAEL D.; WAUGH, JACOB M.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 059300/0169 →
Assignment of Assignor's Interest
Mar 18, 2022
From: RUEGG, CURTIS L.; FAN STONE, HONGRAN; WAUGH, JACOB M.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 059304/0989 →
Assignment of Assignor's Interest
Mar 18, 2022
From: DAKE, MICHAEL D.; WAUGH, JACOB M.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 059303/0532 →
Assignment of Assignor's Interest
Mar 18, 2022
From: THOMPSON, STEWART A.; RUEGG, CURTIS L.; WAUGH, JACOB M.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 059303/0446 →
Release of Security Interest
Feb 7, 2025
From: ATHYRIUM BUFFALO LP
To: REVANCE THERAPEUTICS, INC
Reel/Frame 070153/0630 →
Security Interest
Feb 7, 2025
From: REVANCE THERAPEUTICS, INC.; CROWN LABORATORIES, INC.
To: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
Reel/Frame 070153/0663 →